Nuvalent, Inc. (NUVL)
NASDAQ: NUVL · IEX Real-Time Price · USD
68.88
+0.93 (1.37%)
At close: Apr 30, 2024, 4:00 PM
67.53
-1.35 (-1.96%)
After-hours: Apr 30, 2024, 4:33 PM EDT
Nuvalent Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
92
Market Cap
4.41B USD
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 0 | - | - |
| Dec 31, 2022 | 0 | - | - |
| Dec 31, 2021 | 0 | - | - |
| Dec 31, 2020 | 0 | - | - |
| Dec 31, 2019 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Perrigo Company | 4.66B |
| Alkermes | 1.66B |
| Lantheus Holdings | 1.30B |
| Merit Medical Systems | 1.26B |
| Doximity | 468.33M |
| CRISPR Therapeutics AG | 371.21M |
| Alpine Immune Sciences | 58.88M |
| Krystal Biotech | 50.70M |
NUVL News
- 22 days ago - Nuvalent Presents New Preclinical Data Supporting Profiles of HER2-Selective Inhibitor, NVL-330, and ROS1-Selective Inhibitor, Zidesamtinib, at AACR Annual Meeting 2024 - PRNewsWire
- 2 months ago - Nuvalent to Present New Preclinical Data on HER2-Selective Inhibitor, NVL-330, and ROS1-Selective Inhibitor, zidesamtinib, at AACR Annual Meeting 2024 - PRNewsWire
- 2 months ago - Nuvalent Highlights Pipeline Progress, Reiterates Key Anticipated Milestones and Reports Fourth Quarter and Full Year 2023 Financial Results - PRNewsWire
- 2 months ago - Nuvalent Receives U.S. FDA Breakthrough Therapy Designation for NVL-520 - PRNewsWire
- 2 months ago - Nuvalent Initiates the Phase 2 Portion of ALKOVE-1 Clinical Trial for Patients with ALK-Positive NSCLC and other Solid Tumors - PRNewsWire
- 3 months ago - Nuvalent to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference - PRNewsWire
- 4 months ago - Nuvalent Announces "OnTarget 2026" Operating Plan and Key Anticipated Milestones - PRNewsWire
- 4 months ago - Nuvalent to Present at the 42nd Annual J.P. Morgan Healthcare Conference - PRNewsWire